Corrigendum to “HIV-associated lymphoma” [Best Pract Res Clin Haematol 25 (2012) 101–117, (S1521692612000023), (10.1016/j.beha.2012.01.001)];HIV-associated lymphoma

Best Practice and Research: Clinical Haematology

Volumn 25, Issue 1, 2012, Pages 101-117

  Kaplan, Lawrence D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Burkitt lymphoma; diffuse large B cell lymphoma; Hodgkin lymphoma; human immunodeficiency virus; non Hodgkin lymphoma

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; NAVELBINE; PREDNISONE; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TRANSCRIPTION FACTOR PAX5; VINCRISTINE; ZIDOVUDINE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BACKACHE; BONE MARROW; BONE MARROW SUPPRESSION; BRAIN BIOPSY; BURKITT LYMPHOMA; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); CYTODIAGNOSIS; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; FLOW CYTOMETRY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TRACT; HEADACHE; HEMATOPOIETIC CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN DEFICIENCY; IMMUNOHISTOCHEMISTRY; INFECTION; KAPOSI SARCOMA; KIDNEY FUNCTION; LIVER FUNCTION TEST; LYMPHOCYTE COUNT; MULTIVARIATE ANALYSIS; NAUSEA; NECK PAIN; NEEDLE BIOPSY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PARANASAL SINUS; PREGNANCY TEST; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADICULAR PAIN; RETROSPECTIVE STUDY; SOMATIC HYPERMUTATION; TUMOR CELL; TUMOR CELL DESTRUCTION; VIRUS LOAD;

EID: 84858309735     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2024.101554     Document Type: Erratum

References (100)

1. R.J. Biggar, and C.S. Rabkin The epidemiology of AIDS-related neoplasms Hematol Oncol Clin North Am 10 1996 997
2. R.J. Biggar, P.S. Rosenberg, and T. Coté Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group Int J Cancer 68 1996 754
3. E.A. Engels, R.M. Pfeiffer, and J.J. Goedert Trends in cancer risk among people with AIDS in the United States 1980-2002 AIDS 20 2006 1645
4. J.L. Long, E.A. Engels, and R.D. Moore Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals AIDS 22 2008 489
5. J. Polesel, G.M. Clifford, and M. Rickenbach Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy AIDS 22 2008 301
6. T.R. Coté, R.J. Biggar, and P.S. Rosenberg Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group Int J Cancer 73 1997 645
7. C. Diamond, T.H. Taylor, and T. Aboumrad Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy Cancer 106 2005 128 135
8. P. Balsalobre, J.L. Díez-Martín, and A. Re Autologous stem-cell transplantation in patients with HIV-related lymphoma J Clin Oncol 27 2009 2192
9. A. Carbone, and A. Gloghini Plasmablastic lymphoma: one or more entities? Am J Hematol 83 2008 763 764
10. S.M. Mbulaiteye, R.J. Biggar, and J.J. Goedert Pleural and peritoneal lymphoma among people with AIDS in the United States J Acquir Immune Defic Syndr 29 2002 418
11. I.W. Flinn, and R.F. Ambinder AIDS primary central nervous system lymphoma Curr Opin Oncol 8 1996 373
12. E.A. Engels, R.M. Pfeiffer, and O. Landgren Immunologic and virologic predictors of AIDS-related non-Hodgkin lymphoma in the highly active antiretroviral therapy era J Acquir Immune Defic Syndr 54 2010 78
13. 4): a prospective cohort study Lancet Oncol 10 2009 1152
14. A. Zoufaly, H.J. Stellbrink, and M.A. Heiden Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma J Infect Dis 200 2009 79
15. M. Guech-Ongey, E.P. Simard, and W.F. Anderson AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood 116 2010 5600
16. J. Gabarre, M. Raphael, and E. Lepage Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes Am J Med 111 2001 704
17. P.A. Forsyth, and L.M. DeAngelis Biology and management of AIDS-associated primary CNS lymphomas Hematol Oncol Clin North Am 10 1996 1125
18. S. Franceschi, M. Lise, and G.M. Clifford Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study Br J Cancer 103 2010 416
19. D. Killebrew, and B. Shiramizu Pathogenesis of HIV-associated non-Hodgkin lymphoma Curr HIV Res 2 2004 215
20. A. Biancotto, J.C. Grivel, and S.J. Iglehart Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1 Blood 109 2007 4272
21. A. Carbone Emerging pathways in the development of AIDS-related lymphomas Lancet Oncol 4 2003 22
22. M.J. Kersten, M.R. Klein, and A.M. Holwerda Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma J Clin Invest 99 1997 1525
23. E. Piriou, K. van Dort, and N.M. Nanlohy Loss of EBNA1-specific memory CD4+ and CD8 + T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma Blood 106 2005 3166
24. K.S. Guterman, L.S. Hair, and S. Morgello Epstein-Barr virus and AIDS-related primary central nervous system lymphoma. Viral detection by immunohistochemistry, RNA in situ hybridization, and polymerase chain reaction Clin Neuropathol 15 1996 79
25. A. Carbone, and A. Gloghini AIDS-related lymphomas: from pathogenesis to pathology Br J Haematol 130 2005 662
26. R.G. Nador, E. Cesarman, and A. Chadburn Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus Blood 88 1996 645
27. H.Y. Dong, D.T. Scadden, and L. de Leval Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm Am J Surg Pathol 29 2005 1633
28. J.D. Siebert, R.F. Ambinder, and V.M. Napoli Human immunodeficiency virus-associated Hodgkin's disease contains latent, not replicative, Epstein-Barr virus Hum Pathol 26 1995 1191
29. M. Bower, M. Fisher, and T. Hill CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK Haematologica 94 2009 875
30. J. Abellán-Martínez, J.M. Guerra-Vales, and M.J. Fernández-Cotarelo Evolution of the incidence and aetiology of fever of unknown origin (FUO), and survival in HIV-infected patients after HAART (Highly Active Antiretroviral Therapy) Eur J Intern Med 20 2009 474
31. W. Heise, K. Arastéh, and P. Mostertz Malignant gastrointestinal lymphomas in patients with AIDS Digestion 58 1997 218
32. C. Diamond, T.H. Taylor, and T. Aboumrad Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival Cancer 106 2006 128
33. L.D. Kaplan, D.J. Straus, and M.A. Testa Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group N Engl J Med 336 1997 1641
34. D. Sarker, C. Thirlwell, and M. Nelson Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma AIDS 17 2003 861
35. A. Cingolani, R. Gastaldi, and L. Fassone Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas J Clin Oncol 18 2000 3325
36. U. Hegde, A. Filie, and R.F. Little High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology Blood 105 2005 496
37. J.T. Navarro, F. Vall-Llovera, and J.L. Mate Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART Haematologica 93 2008 149
38. D.J. Straus Human immunodeficiency virus-associated lymphomas Med Clin North Am 81 1997 495
39. J. Castillo, L. Pantanowitz, and B.J. Dezube HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases Am J Hematol 83 2008 804
40. D.J. Riedel, L.F. Gonzalez-Cuyar, and X.F. Zhao Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection Lancet Infect Dis 8 2008 261
41. C. Simonelli, M. Spina, and R. Cinelli Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study J Clin Oncol 21 2003 3948
42. M. Ladanyi, K. Offit, and S.C. Jhanwar Myc rearrangements and translocations involving band 8q24 in diffuse large-cell lymphomas Blood 77 1991 1057 1063
43. S.H. Swerdlow, E. Campo, and N.L. Harris WHO classification of tumours of haematopoietic and lymphoid tissues 2008 IARC Lyon
44. J.A. Moormeier, S.F. Williams, and H.M. Golomb The staging of non-Hodgkin's lymphomas Semin Oncol 17 1990 43
45. R.F. Little, S. Pittaluga, and N. Grant Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology Blood 101 2003 4653
46. J.A. Sparano, J.Y. Lee, and L.D. Kaplan Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma Blood 115 2010 3008
47. M. Spina, U. Jaeger, and J.A. Sparano Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials Blood 105 2005 1891
48. F. Boué, J. Gabarre, and C. Gisselbrecht Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma J Clin Oncol 24 2006 4123
49. D.J. Straus, J. Huang, and M.A. Testa Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142 - low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases J Clin Oncol 16 1998 3601
50. N. Mounier, M. Spina, and J. Gabarre AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy Blood 107 2006 3832
51. M. Bower, B. Gazzard, and S. Mandalia A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy Ann Intern Med 143 2005 265
52. J.J. Castillo, E.S. Winer, and D. Stachurski Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma Oncologist 15 2010 293 299
53. C.P. Hans, D.D. Weisenburger, and T.C. Greiner Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood September 22, 2003 2003-05-1545
54. S.T. Lim, R. Karim, and A. Tulpule Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy J Clin Oncol 23 2005 8477
55. R. Weiss, P. Mitrou, and K. Arasteh Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival - results of the German Multicenter Trial Cancer 106 2006 1560
56. E. Vaccher, M. Spina, and G. di Gennaro Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma Cancer 91 2001 155
57. A. Antinori, A. Cingolani, and L. Alba Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy AIDS 15 2001 1483
58. M. Bower, N. McCall-Peat, and N. Ryan Protease inhibitors potentiate chemotherapy-induced neutropenia Blood 104 2004 2943
59. L. Ratner, J. Lee, S. Tang AIDS Malignancy Consortium Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy J Clin Oncol 19 8 2001 2171 2178 (Pubitemid 32366971)
60. B. Coiffier, E. Lepage, and J. Briere CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 2002 235
61. J.M. Ribera, A. Oriol, and M. Morgades Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial Br J Haematol 140 2008 411
62. L.D. Kaplan, J.Y. Lee, and R.F. Ambinder Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010 Blood 106 2005 1538
63. W.H. Wilson, M.L. Grossbard, and S. Pittaluga Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy Blood 99 2002 2685 2693 (Pubitemid 34525353)
64. K. Dunleavy, R.F. Little, and S. Pittaluga The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma Blood 115 2010 3017
65. K. Dunleavy, S. Pittaluga, and M.S. Czuczman Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma Blood 113 2009 6069 6076
66. S.T. Lim, R. Karim, and B.N. Nathwani AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy J Clin Oncol 23 2005 4430
67. A. Lacasce, O. Howard, and S. Li Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity Leuk Lymphoma 45 2004 761 767 (Pubitemid 38256039)
68. E.S. Wang, D.J. Straus, and J. Teruya-Feldstein Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma Cancer 98 2003 1196
69. A. Noy, L. Kaplan, and J. Lee Feasibility and toxicity of a modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt and atypical Burkitt lymphoma (BL): preliminary results of a prospective multicenter phase II trial of the AIDS Malignancy Consortium (AMC) Blood (ASH Annual Meeting Abstracts) 114 2009 abstract3673
70. J. Teruya-Feldstein, E. Chiao, and D.A. Filippa CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients Ann Oncol 15 2004 1673
71. J. Bi, B.M. Espina, and A. Tulpule High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma J Acquir Immune Defic Syndr 28 2001 416
72. J. Gabarre, N. Azar, and B. Autran High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma Lancet 355 2000 1071
73. A. Krishnan, A. Molina, and J. Zaia Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas Blood 105 2005 874
74. A. Re, M. Michieli, and S. Casari High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors Blood 114 2009 1306
75. D. Serrano, P. Miralles, and P. Balsalobre Hematopoietic stem cell transplantation in patients infected with HIV Curr HIV/AIDS Rep 7 2010 175 184
76. T.R. Spitzer, R.F. Ambinder, and J.Y. Lee Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020 Biol Blood Marrow Transplant 14 2008 59
77. V. Gupta, M. Tomblyn, and T.L. Pedersen Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research Biol Blood Marrow Transplant 15 2009 864
78. E.A. Maher, and H.A. Fine Primary CNS lymphoma Semin Oncol 26 1999 346
79. B.A. Johnson, E.K. Fram, and P.C. Johnson The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features AJNR Am J Neuroradiol 18 1997 563
80. M.M. Thurnher, S.A. Thurnher, and E. Schindler CNS involvement in AIDS: spectrum of CT and MR findings Eur Radiol 7 1997 1091
81. A. Antinori, A. Ammassari, and A. De Luca Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF Neurology 48 1997 687
82. L.E. Raez, P. Patel, and L. Feun Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL) Crit Rev Oncog 9 1998 199
83. J.E. Baumgartner, J.R. Rachlin, and J.H. Beckstead Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome J Neurosurg 73 1990 206
84. C. Jacomet, P.M. Girard, and M.G. Lebrette Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS AIDS 11 1997 1725
85. T. Batchelor, K. Carson, and A. O'Neill Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07 J Clin Oncol 21 2003 1044 1049 (Pubitemid 46594133)
86. James L. Rubenstein, Jeffrey L. Johnson, and Sin-Ho Jung Intensive chemotherapy and immunotherapy, without brain irradiation Newly diagnosed patients with primary CNS lymphoma: results of CALGB 50202 Blood (ASH Annual Meeting Abstracts) vol. 116 Nov 2010 763
87. T. Powles, D. Robinson, and J. Stebbing Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection J Clin Oncol 27 2009 884 890
88. R.J. Biggar, E.S. Jaffe, and J.J. Goedert Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS Blood 108 2006 3786 3791 (Pubitemid 44864560)
89. S.L. Glaser, C.A. Clarke, and M.L. Gulley Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998 Cancer 98 2003 300 309 (Pubitemid 36828454)
90. P. Hartmann, U. Rehwald, and B. Salzberger Current treatment strategies for patients with Hodgkin's lymphoma and HIV infection Expert Rev Anticancer Ther 4 2004 401
91. A.M. Levine, P. Li, and T. Cheung Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149) J Acquir Immune Defic Syndr 24 2000 444
92. U. Tirelli, D. Errante, and R. Dolcetti Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors J Clin Oncol 13 1995 1758 1767
93. B. Xicoy, J.M. Ribera, and P. Miralles Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma Haematologica 92 2007 191
94. M. Spina, J. Gabarre, and G. Rossi Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection Blood 100 2002 1984
95. M. Spina, G. Rossi, and A. Antinori VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV) Annals of Oncology 19 2008 iv152 abstract 227
96. P. Hartmann, U. Rehwald, and B. Salzberger BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection Ann Oncol 14 2003 1562 1569 (Pubitemid 37304614)
97. M.C. Cheung, L.K. Hicks, and H.A. Leitch Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma Clin Lymphoma Myeloma Leuk 10 2010 E22 E25
98. W.G. Martin, K.M. Ristow, and T.M. Habermann Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma J Clin Oncol 23 2005 7614 7620 (Pubitemid 46291825)
99. A.M. Evens, J. Cilley, and T. Ortiz G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis Br J Haematol 137 2007 545 552 (Pubitemid 46817335)
100. R.G. Jenner, K. Maillard, and N. Cattini Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile Proc Natl Acad Sci USA 100 2003 10399 10404 (Pubitemid 37071890)